Illumina reaffirms commitment to the National Project of Bio Big Data in Korea
PR91702
MELBOURNE, Australia, Sept. 20, 2021 /PRNewswire=KYODO JBN/ --
Illumina, Inc. (NASDAQ: ILMN) today announced that the National Project of Bio
Big Data in Korea has selected Illumina technology for the second pilot project
in their effort to work towards establishing a national digital library on
health and genome data by 2028.
The multi-ministerial project is overseen by the Ministry of Health and
Welfare, Ministry of Trade and Industry, Ministry of Science and ICT, and Korea
Disease Control and Prevention Agency. The second pilot will continue to use
the NovaSeq(TM) 6000, Illumina's high-throughput DNA sequencing instrument and
DRAGEN™ Bio-IT Platform analysis tool.
After setting the stage in the first pilot project, establishing a database of
10,000 genomes, the consortium comprising Macrogen, Theragen, DNA Link and Lab
Genomics was again selected after a competitive evaluation process that
highlighted the overall superiority of Illumina's next-generation sequencing
(NGS) platforms.
The second pilot project will analyze the genetic makeup of 12,500 donated DNA
samples from Korean patients living with a rare disease.
"Whole-genome sequencing is a powerful tool to identify and analyze the genetic
information of patients living with a rare disease and can help end the long
search for a diagnosis which can take several years," said Sukang lee, CEO
Macrogen. "We are grateful for Illumina's partnership in enabling this
important research".
Illumina Vice President and General Manager of Asia Pacific and Japan, Ms
Gretchen Weightman, explained that Illumina will continue to bring
industry-leading genomic technologies and expertise to deploy the sequencing
architecture, data infrastructure and analytical tools that will reveal new
insights into the Korean genome.
"We are pleased to continue working with our partners to accelerate the future
of health care for Koreans and contribute to the development of treatment
technologies and therapeutics," Ms Weightman said.
Over the next year, the resulting data will be used by the Illumina backed
consortium to prepare for the main project in analyzing and comparing the genes
of 1 million Koreans to advance the country's medical technology and improve
future public health.
ABOUT ILLUMINA
Illumina is improving human health by unlocking the power of the genome. Our
focus on innovation has established us as the global leader in DNA sequencing
and array-based technologies, serving customers in the research, clinical, and
applied markets. Our products are used for applications in the life sciences,
oncology, reproductive health, agriculture, and other emerging segments. To
learn more, visit www.illumina.com and connect with us on Twitter (
), Facebook (
), LinkedIn (
), Instagram (
), and YouTube (
).
Investors:
Brian Blanchett
+1.858.291.6421
ir@illumina.com
Media:
Dr. Karen Birmingham
+1.646.355.2111
kbirmingham@illumina.com
SOURCE: Illumina, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
